For questions regarding claiming CME Credit, please refer to our FAQ section.

 
Late Breaking Trials from ACC, CIT and EuroPCR:   Bivalirudin vs. Heparin in STEMI

Program Overview:

Trial reports from the Spring 2014 meetings have muddied the controversies regarding bivalirudin versus heparin for PCI.  Both bivalirudin and heparin are Level I recommendations as adjunct anticoagulants during PCI for STEMI. Bivalirudin is recommended over heparin when elevated bleeding risk is present because of the mortality benefit from reduced bleeding events including those that occur periprocedurally. However, bivalirudin’s high cost and increased risk of stent thrombosis remain drawbacks.

This webcast will revisit the collective issue of bivalirudin vs heparin for STEMI PCI.  

Click Here to access this CME Program  
Release Date:
October 16th, 2014

Expiration Date:
April 16th, 2015 

Estimated Time:
1 hour   

DAPT CME Program Overview:

This webcast examines common clinical dilemmas with dual antiplatelet therapy including noncardiac surgeries, DAPT plus anticoagulants for atrial fibrillation patients post-PCI, and managing bleeding complications with DAPT or triple therapy. Clinical tools and recent clinical trial data are discussed to help physicians with decision-making around DAPT.

Click Here to access this CME Program  
Release Date:
October 16th, 2014

Expiration Date:
April 16th, 2015 

Estimated Time:
1 hour  


Post ACC 14: Focus on TAVR Program Overview:

Over 50,000 TAVR procedures have been performed globally.1 With the development of multiple systems for TAVR, best practice questions have formed. Late-breaking trials from ACC offered an examination of key topics including comparison of TAVR devices and post-marketing safety in the United States to further refine the use of this technology and insights into device and patient selection. Results discussed include:

  • CoreValve in high-risk surgical patients vs surgical aortic valve replacement
  • CHOICE trial comparing the two available TAVR systems—balloon expandable (Sapien) and self-expanding (CoreValve)
  • One-year outcomes from the STS/ACC Transcatheter Valve Therapy Registry

Click Here to access this CME Program

Release Date: 
June 16th, 2014

Expiration Date: 
December 16th, 2014
 
Estimated Time: 
1 hour  


ACC 14: Focus on Renal Denervation Program Overview:

One-in-ten hypertension cases is treatment resistant (ie, inadequate response with 3 or more antihypertensives). While renal denervation has proven safe for treating severe hypertension, the latest results from SYMPLICITY HTN-3 render its efficacy unclear. Patient selection remains one of the biggest challenges, as 20% of patients are non-responders in clinical trials. At ACC 2014, SYMPLICITY HTN-3 primary results and the Global SYMPLICITY registry, which looks at post-approval real-world outcomes on multiple continents, were presented. This webcast will review key results. A panel discussion will provide context for the SYMPLICITY HTN-3 and GLOBAL SYMPLICITY results and implications for the field of renal denervation.

Click Here to access this CME Program  
Release Date:
June 16th, 2014

Expiration Date:
December 16th, 2014
 
Estimated Time:
1 hour   


Future of Valve Surgery CME Webcast Program Overview:

This program is geared toward the surgeon seeking to gain confidence in performing minimally invasive valve procedures. Participants will discuss the clinical and practical aspects involved in establishing a successful structural heart and valve program. In addition, sessions will examine new technological developments in the field, such as stented and sutureless valves, as well as future directions in valvular repair and replacement.

Click Here to access this CME Program

Release Date:
May 28th, 2014

Expiration Date:
November 28, 2014

Estimated Time:
45 Minutes